(July 6, 2018, 1:50 PM EDT) -- CHICAGO — The Illinois federal judge overseeing the testosterone replacement therapy multidistrict litigation on July 5 vacated a $140.14 million verdict in the second AndroGel bellwether trial, finding the jury’s inconsistent verdict on the same causation evidence warranted a new trial (In Re: Testosterone Replacement Therapy Products Liability Litigation, MDL Docket No. 2545, No. 14-1748, Jeffrey Konrad v. AbbVie, Inc., et al., No. 15-966, N.D. Ill., E. Div., 2018 U.S. Dist. LEXIS 111724)....